ENDRA Life Sciences (NDRA) Share-based Compensation (2016 - 2026)

ENDRA Life Sciences has disclosed Share-based Compensation across 11 years of filings, most recently posting $574451.0 for Q1 2026.

• In Q1 2026, Share-based Compensation rose 591.73% year-over-year to $574451.0; the TTM figure through Mar 2026 stood at $731624.0 (up 116.79% YoY), while the FY2025 annual figure was $329409.0, down 42.4% from the prior year.
• Share-based Compensation climbed to $574451.0 in Q1 2026, from $12878.0 in the prior quarter.
• Over the last five years, Share-based Compensation for NDRA reached as high as $909069.0 in Q3 2022 and fell as low as -$288537.0 in Q2 2022.
• The 5-year median for Share-based Compensation is $237279.0 (2023), against an average of $210756.6.
• Annual changes were most pronounced in 2022 — Share-based Compensation plunged 175.32% — and 2026, when it jumped 591.73%.
• A 5-year view of Share-based Compensation shows it stood at $290769.0 in 2022, then slipped by 13.83% to $250557.0 in 2023, then slumped by 58.22% to $104684.0 in 2024, then sank by 87.7% to $12878.0 in 2025, then soared by 4360.72% to $574451.0 in 2026.
• According to Business Quant data, Share-based Compensation over the past three periods registered $574451.0, $12878.0, and $104765.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.